ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 138

Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout

Michael George1, Sally W. Pullman-Mooar2 and H. Ralph Schumacher3, 1Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, 3Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Colchicine, Gout and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Colchicine is recommended to prevent gout flares in patients initiating and increasing uric acid lowering therapy until serum uric acid is ≤ 6 mg/dL. Many patients, however, are prescribed colchicine without adequate urate lowering therapy or remain on colchicine after uric acid targets have been met. The recent dramatic increase in colchicine cost in the United States has made it even more important to examine current prescribing practices, identify variables that influence these practices, and promote appropriate colchicine use.

Methods: Pharmacy identified 193 patients at a VA medical center with active outpatient colchicine prescriptions on 11/4/2011. Electronic medical record review revealed 126 patients prescribed colchicine for ≥ 30 days for prophylaxis of gout flares. Colchicine prescribing was defined as inappropriate if 1) no concurrent urate lowering therapy was prescribed, 2) uric acid was not at goal and urate lowering therapy had not been initiated or increased in the past 3 months, or 3) uric acid goals were met for > 1 year and flares had resolved in the absence of tophi. Demographic and clinical variables in appropriate and inappropriate groups were compared.

Results: Of 126 patients prescribed prophylactic colchicine, 34 (27.0%) were prescribed no urate lowering therapy, 50 (39.7%) were not at uric acid goal and had not had urate lowering therapy increased in the prior 3 months, and 9 (7.1%) were at uric acid goal for more than one year with no flares or tophi. Colchicine use was considered appropriate in 33 patients (26.2%) – 20 (15.9%) with urate lowering therapy initiated or increased in the past 3 months, 12 (9.5%) at uric acid target for < 1 year, and 1 (0.8%) at uric acid target for > 1 year but with continued flares. Patients appropriately prescribed colchicine were younger, had shorter time on colchicine, and were more likely to have been seen by Rheumatology as opposed to being managed solely by primary care.  Allopurinol dose and allergy, uric acid level, and renal function were similar in the two groups (see table).

Conclusion: Our results demonstrate a high incidence of what we considered inappropriate prophylactic colchicine use, driven largely by failure to prescribe concurrent urate lowering therapy or adequately increase these medications. Rheumatology consultation was associated with improved colchicine prescribing. Increased education of primary care physicians about current standards of care is needed to avoid unnecessary colchicine exposure and excessive health care system costs.

Comparison of Patients Appropriately and Inappropriately Prescribed Prophylactic Colchicine

 

Appropriate (N=33)

Inappropriate (N=93)

P Value

Age, yrs

65 [33-89]

70 [37-89]

0.01

Male, no. (%)

33 (100.0)

92 (98.9)

1.0

Colchicine daily dose, mg

0.6 [0.3-1.2]

0.6 [0.3-1.2]

0.57

Time on colchicine, yrs

1.12 [0.07-17.4]

3.26 [0.05-14.1]

0.0002

Allopurinol dose, mg

200 [100-400]

200 [100-400]

0.34

Allopurinol allergy, no. (%)

1 (3.0)

7 (7.5)

0.36

Crystal confirmed, no. (%)

33 (42.4)

37 (39.8)

0.79

Uric acid level, mg/dL

6.7 [4.2-14.2]

7.4 [3.6-13.2]

0.36

Creatinine, mg/dL

1.29 [0.8-2.3]

1.24 [0.7-2.9]

0.93

GFR, mL/min/1.73m2

64 [37-126]

67 [27-144]

0.87

Rheumatology visit ≤ 1 yr, no. (%)

19 (57.6)

20 (21.5)

< 0.0001

Rheumatology visit ever, no. (%)

25 (75.8)

51 (54.8)

0.04

Skewed data expressed as median [range]. Percentages may not add up to 100 because of rounding.


Disclosure:

M. George,
None;

S. W. Pullman-Mooar,
None;

H. R. Schumacher,

Takeda, Wyeth,

2,

Regeneron, Novartis, Ardea, Pfizer, Savient, Metabolex,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-appropriate-use-of-prophylactic-colchicine-and-urate-lowering-therapy-in-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology